Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccine therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    366 result(s) found for: Vaccine therapy. Displaying page 2 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-002715-38 Sponsor Protocol Number: APHP220775 Start Date*: 2023-03-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech...
    Medical condition: Adults who received at least 3 doses of mRNA Covid 19 vaccine (BioNTech-Pfizer and/or Moderna), the last dose received at least 6 months prior to the inclusion in the trial.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003523-30 Sponsor Protocol Number: 38RC17.191 Start Date*: 2017-12-18
    Sponsor Name:University Hospital Grenoble
    Full Title: Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3.
    Medical condition: Our aim is to determine whether an additional dose of inactivated vaccine can increase the rate of responders among patients who have not responded adequately after 3 injections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001459-15 Sponsor Protocol Number: HS-2021-02 Start Date*: 2021-04-26
    Sponsor Name:Medical University of Graz
    Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study
    Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005026-20 Sponsor Protocol Number: mRNA-1345-P301 Start Date*: 2022-08-04
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003191-14 Sponsor Protocol Number: 21CH135 Start Date*: 2021-08-16
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Jan...
    Medical condition: volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004272-17 Sponsor Protocol Number: CLO-SCB-2019-003 Start Date*: 2021-03-25
    Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd
    Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S...
    Medical condition: SARS-CoV-2-mediated COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003866-14 Sponsor Protocol Number: B5091007 Start Date*: 2017-06-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
    Medical condition: Primary C difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001735-10 Sponsor Protocol Number: 21816 Start Date*: 2021-05-28
    Sponsor Name:Bayer AG
    Full Title: COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in parti...
    Medical condition: Vaccination for prophylaxis of coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020233-56 Sponsor Protocol Number: DC-006 Start Date*: 2011-03-24
    Sponsor Name:Oslo University Hospital
    Full Title: PHASE I/II TRIAL OF VACCINE THERAPY IN RELAPSED AND PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS USING AUTOLOGOUS DENDRITIC CELLS LOADED WITH AMPLIFIED OVARIAN CANCER STEM CELL mRNA, hTE...
    Medical condition: Relapsed and platinum resistant epithelial ovarian carcinoma patients that have received one line of non-platinum chemotherapy in resistance disease setting.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001228-32 Sponsor Protocol Number: COV002 Start Date*: 2020-05-04
    Sponsor Name:CTRG
    Full Title: A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003651-20 Sponsor Protocol Number: V211-017 Start Date*: 2007-06-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
    Medical condition: Zoster Vaccine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001040-10 Sponsor Protocol Number: CoVVac Start Date*: 2021-04-26
    Sponsor Name:Medical University of Graz
    Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study
    Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals.
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000291-11 Sponsor Protocol Number: IMRES Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19)
    Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011587-11 Sponsor Protocol Number: RHMCAN0658 Start Date*: 2010-02-11
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: INVESTIGATING THE CLINICAL USE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PREVENAR)IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
    Medical condition: Childhood Acute Lymphoblastic Leukaemia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004708-21 Sponsor Protocol Number: A3L44 Start Date*: 2019-07-23
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected In...
    Medical condition: DTaP-IPV-HB-PRP-T Combined Vaccine in Human Immunodeficiency Virus Exposed Infected and Uninfected Infants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002452-40 Sponsor Protocol Number: Td500056 Start Date*: 2023-03-08
    Sponsor Name:Sanofi Pasteur
    Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg...
    Medical condition: Bacterial infections
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    21.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    21.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003438-18 Sponsor Protocol Number: 116428 Start Date*: 2013-01-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomised, observer-blind, placebo-controlled, multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered in...
    Medical condition: Vaccination against HZ in adults with haematologic malignancies.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) FI (Completed) ES (Completed) IT (Completed) CZ (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003429-28 Sponsor Protocol Number: 109823 Start Date*: 2014-04-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscul...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10071147 Human papilloma virus immunization LLT
    19.0 100000004848 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: EE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:50:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA